Business Context and Reporting Period
Company: Virios Therapeutics, Inc. (Note: Request metadata listed "Dogwood Therapeutics," but the filing text identifies the registrant as Virios Therapeutics, Inc., trading as VIRI).
Reporting Period: Quarterly period ended June 30, 2024 (Form 10-Q).
Business Overview: Virios is a pre-revenue, development-stage biotechnology company focused on novel antiviral therapies for diseases associated with dormant herpesvirus activation, specifically fibromyalgia (FM) and Long-COVID (LC). Lead candidates include IMC-1 (famciclovir/celecoxib) and IMC-2 (valacyclovir/celecoxib).
Key Financial Metrics
| Metric | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2024 | As of June 30, 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(1,049,833) | $(2,341,168) | N/A |
| Loss Per Share (Basic/Diluted) | $(0.05) | $(0.11) | N/A |
| Operating Expenses | $1,069,824 | $2,383,925 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $3,020,183 |
| Total Assets | N/A | N/A | $3,635,889 |
| Total Liabilities | N/A | N/A | $500,076 |
| Stockholders' Equity | N/A | N/A | $3,135,813 |
| Accumulated Deficit | N/A | N/A | $(63,810,390) |
Cash Flow (Six Months Ended June 30, 2024):
- Net cash used in operating activities: $(1,749,160)
- Net cash provided by financing activities: $1,452,397 (primarily from public offering)
- Net decrease in cash: $(296,763)
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses decreased by approximately $0.4 million for the six months ended June 30, 2024, compared to the same period in 2023. This was driven by reductions in drug development, manufacturing, toxicology studies, and regulatory consulting costs.
- Net Loss: Net loss decreased by approximately $0.6 million for the six-month period compared to the prior year.
- Capital Raise: In May 2024, the Company completed a public offering of 8,500,000 shares at $0.20 per share, raising gross proceeds of $1.7 million and net proceeds of approximately $1.4 million. No equity financings occurred in the comparable 2023 period.
- Share Count: Weighted average shares outstanding increased significantly due to the May 2024 offering.
Outlook, Risks, and Management Commentary
Going Concern: Management has expressed substantial doubt about the Company's ability to continue as a going concern for at least 12 months from the filing date. Current cash of $3.0 million is insufficient to fund operations for the next year. Additional capital is required within the next six months.
Clinical Development:
- Long-COVID (LC): The Company is funding a double-blinded, placebo-controlled study at the Bateman Horne Center (BHC) using IMC-2. Enrollment is complete, with results expected in October 2024.
- Fibromyalgia (FM): The Company is focusing on "new" FM patients based on post-hoc analysis of the FORTRESS study. FDA feedback in 2023 indicated the proposed Phase 3 program is amenable pending toxicology review.
Nasdaq Listing Compliance: The Company received notice from Nasdaq that its stock price has been below the $1.00 minimum bid price requirement. An exception was granted until October 28, 2024, to regain compliance. If compliance is not achieved by October 11, 2024, a reverse stock split will be required. Failure to comply by October 28, 2024, will result in delisting.
Cost Reductions: Effective March 1, 2024, employees accepted a 10% salary reduction and directors accepted a 10% fee reduction in exchange for future vesting stock options.
Investor Verification Checklist
- Liquidity Runway: Verify the timeline and certainty of the next capital raise required within six months to avoid insolvency.
- Nasdaq Compliance: Monitor stock price performance to determine if a reverse stock split is necessary before the October 28, 2024 deadline.
- Clinical Trial Results: Await the October 2024 results from the BHC Long-COVID study, which is critical for future valuation and funding.
- Dilution Risk: Assess the impact of future equity offerings required to fund operations on existing shareholder value.
- Going Concern Status: Review the "Going Concern" note in the financial statements for details on the substantial doubt regarding future operations.